Locations

Berlin, Germany · Berlin, Germany · 7800 Skive, Denmark

industry

Biotechnology · Health Care · Life Science · Therapeutics

Size

1 - 10 employees

founded in

2019

Tacalyx, a spin-off from the Max-Planck-Institute of Colloids and Interfaces, Potsdam, Germany (MPICI), focuses on Tumor-Associated Carbohydrate Antigens (TACAs) as a novel target class for cancer treatment. The highly tumor-specific expression of TACAs results from aberrant glycosylation and promotes metastasis, angiogenesis, and suppression of the immune system. Tacalyx uses the sophisticated technology of carbohydrate synthesis to synthesize highly pure TACA structures for the generation and identification of antibodies that will be developed into novel therapeutics for the treatment of cancer.

Something looks off?
Open jobs at Tacalyx
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.